Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the role of the androgen receptor in regulating development and homeostasis, and reviews treatment approaches for conditions related to hormone imbalances, without reporting new clinical findings.

In this study, researchers found no significant differences in serum levels of DHEAs, DHT, and testosterone between female patients with oral lichen planus and healthy controls, suggesting no neuroendocrine etiology linked to the condition.

This review highlights that bicalutamide, a non-steroidal antiandrogen used in prostate cancer treatment, is mainly effective through its (R)-enantiomer and emphasizes the need to monitor its adverse effects despite its targeted antiandrogenic action.

In this study, researchers found no significant differences in the serum levels of DHEAs, DHT, and testosterone between female patients with oral lichen planus and healthy controls, suggesting no neuroendocrine etiology is associated with this condition.

This study developed a new analytical method to identify a wide range of endocrine disrupting compounds in full-term amniotic fluid, revealing diverse substances with potential endocrine activity.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

This review discusses drugs and mechanisms possibly responsible for chemical- and drug-induced hair loss but presents no new research findings.

Sex hormones affect reproduction, sexual development, and oral health, and it's important for dental practitioners to understand their effects and interactions.

This review discusses dermatologic issues specific to transgender patients undergoing hormonal therapy and offers guidance for dermatology providers, but does not report new clinical results.

This article provides a reference guide for various dermatological terms, treatments, and conditions, but reports no new clinical findings.

This study found that topical fluridil increased the anagen percentage in men with androgenetic alopecia without causing irritation or systemic side effects.

This study found that treatment with the pure antiandrogen Flutamide did not affect the estrous cycle or plasma levels of most hormones in female rats, supporting its potential use for treating hirsutism, acne, and alopecia in women.

This review discusses various alternative treatments for androgenetic alopecia, including pharmacological, surgical, and herbal therapies, without presenting new clinical findings.

This study discusses the physiopathogeny, clinical manifestations, and treatment objectives of androgenetic alopecia without reporting new clinical findings.

This study is investigating the efficacy and safety of proxalutamide, an androgen receptor antagonist, in treating severe or critically ill patients with COVID-19, aiming to provide new insights into potential therapeutic options. Results are not reported yet.

This study introduced a new spectrofluorometric method using a synthesized organic fluorophore to effectively analyze darolutamide and thalidomide in pharmaceutical preparations and biofluids.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

This review discusses the use of antiandrogens like flutamide and its derivatives in prostate cancer treatment and highlights the need for next-generation antiandrogens for improved efficacy; it reports no new clinical results.

This study developed and tested Bicalutamide-loaded lipid vesicles in dissolving microarray patches for topical application, finding that they effectively deliver Bicalutamide through murine skin while maintaining a favorable safety profile, suggesting potential to improve treatments for androgenetic alopecia.

This study developed a niosomal delivery system loaded with tretinoin and bicalutamide, optimized for follicular targeting in acne management, showing promising accumulation in hair follicles in animal models.

This source explores the potential use of oral bicalutamide for treating female pattern hair loss, but specific results or outcomes from the study are not reported in the abstract.

This abstract discusses the efficacy of spironolactone, cyproterone acetate, and flutamide in treating female pattern hair loss, noting that flutamide use requires caution due to potential liver toxicity, especially at high doses.

This case series evaluated the use of oral bicalutamide with low-dose oral minoxidil in women with female pattern hair loss who didn't respond to minoxidil alone, finding that 96.6% showed improvement after six months without adverse effects.

This case report found that a 48-year-old woman with idiopathic twenty-nail dystrophy experienced significant improvement in nail appearance after six months of treatment with oral Upadacitinib.

This study found that proxalutamide improved immunologic, inflammatory, thrombotic, and oxygen markers in both female and male COVID-19 outpatients, which may support its association with lower hospitalization rates compared to standard care.

In this study, candidate compound 39 demonstrated potent androgen receptor antagonism and faster hair-growth efficacy in a mouse model compared to pyrilutamide, while maintaining favorable safety and pharmacokinetic profiles, suggesting potential for topical use in androgenic alopecia.

This review highlights bicalutamide as a promising oral therapy for female pattern hair loss, noting its safety, tolerability, and effectiveness in women with hyperandrogenic symptoms like acne and hirsutism, though further trials are needed to confirm its ideal dose and efficacy.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.

This study observed that hepatotoxicity is a rare but possible event in hyperandrogenic young females treated with low- and ultralow-dose flutamide, regardless of dose or oral contraceptive use.